IXICO reports 23% revenue rise as order book surges 38% in first half

IXICO PLC (LSE:IXI, OTC:PHYOF, FRA:PYPB), the neuroscience imaging and data analytics company, has reported strong first-half trading with revenues expected to rise 23% to £3.9 million for the six months ended 31 March. The company said growth was driven by new contract wins, contract extensions and increased volumes of biomarker analysis, the measurement of biological indicators used to track disease progression in clinical trials.